dc.identifier.citation |
1] K. L. Alikatte, B. R. Aakondi, V. G. Yerragunta, P.R. Veerareddy, S. Palle, “Antiamnesic activity of Syzygium cumini against scopolamine induced spatial memory impairments in rats,” Brain Dev, vol. 34, pp. 844-851, 2012. [2] R.N. Kalaria, G.E. Maestre, R. Arizaga, R.P. Friedland, D. Galasko, K. Hall, J.A. Luchsinger, A. Ogunniyi, E.K. Perry, F. Potocnik, M. Prince, R. Stewart, A. Wimo, Z. Zhang, and P. Antuono, “Alzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factors,” The Lancet Neurology, vol. 7, pp. 812– 826, 2008. [3] J.L. Cummings, H.V. Vinters, G.M. Cole, and Z.S. Khachaturian, “Alzheimer’s disease: etiologies, pathophysiology, cognitive reserve and treatment opportunities,” Neurology, vol. 51, S2–S17, 1988. [4] P.T. Francis, A.M. Palmer, M. Snape, and G.K. Wilcock, “The cholinergic hypothesis of Alzheimer’s disease: a review of progress,” Journal of Neurology Neurosurgery and Psychiatry, vol. 66, pp. 137– 147, 1999. [5] D.K. Lahiri, M.R. Farlow, N.H. Greig, and K. Sambamurti, “Current drug targets for Alzheimer’s disease treatment,” Drug Development Research, vol. 56, pp. 267-281, 2002. [6] S. Thompson, K.L. Lanctot, and N. Herrmann, “The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease,” Expert Opinion on Drug Safety, vol. 3, pp. 425–440, 2004. 7] L. Fang, B. Kraus, J. Lehmann, J. Heilmann, Y. Zhang, and M. Decker, “Design and synthesis of tacrine–ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates,” Bioorganic and Medicinal Chemistry Letters, vol. 18, pp. 2905–2909, 2008. [8] V. Singh, S. Amdekar, and O. Verma, “Ocimum sanctum (tulsi): Biopharmacological activities”, Webmed central pharmacology, vol. 1, WMC001046, 2010. [9] A. Paton, “A synopsis of Ocimum L. (Labiatae) in Africa,” Kew Bull, vol. 47, pp. 405, 1992. [10] N-A. Zeggwagh, and M. Eddouks, “Anti-hyperglycaemic and hypolipidemic effects of Ocimum basilicum aqueous extract in diabetic rats,” American Journal of Pharmacology and Toxicology, vol. 2, issue 3, pp. 123-129, 2007. [11] M.S. Akhtar, and M. Munir, “Evaluation of the gastric antiulcerugenic effects of Solanum nigrum, Brassica oleracea and Ocimum basilicum in rats,” J Ethnopharmacol, vol. 27, pp. 163–171, 1989. [12] K. Ilhan, Y. Nazife, and B. Mehlika, “Antimicrobial activity of various extracts of Ocimum basilicum L. and observation of the inhibition effect on bacterial cells by use of scanning electron microscopy,” Afr J Trad CAM , vol. 5, pp. 363–369, 2008. [13] T. Dasgupta, A. R. Rao, and P. K. Yadava, “Chemomodulatory efficacy of Basil leaf (Ocimum basilicum) on drug metabolizing and antioxidant enzymes, and on carcinogen-induced skin and forestomach papillomagenesis,” Phytomedicine, vol. 11, pp. 139–151, 2004. [14] O. Stajkovic, B. Tanja, M. Dragana, S. Slavisa, V. G. Branka, S. Draga, and K. V. Jelena, “Antimutagenic properties of Basil (Ocimum basilicum L.) in Salmonella typhimurium TA100,” Food Technol Biotechnol, vol. 45, pp. 213–217, 2007. [15] E. Capecka, A. Mareczek, and B. M. Leja, “Antioxidant activity of fresh and dry herbs of some Lamiaceae species,” Food Chem, vol. 93, pp. 223–226, 2005. [16] A. Umar, G. Imam, W. Yimin, and P. Kerim, “Anti-hypertensive effects of L. on blood pressure in renovascular hypertensive rats,” Hyperten Res, vol. 33, pp. 723–730, 2010. [17] A. F. Blank, Y.R. Rosa, J. L. Carvalho Filho, C.A. Santos, M. F. Arrigoni-Blank, E. S. Niculau, et al, “A diallel study of yield components and essential oil constituents in basil (Ocimum basilicum L.), ” Ind Crops Prod, vol. 38, pp. 93-98, 2012. [18] R. J. Grayer, G. C. Kite, F. J. Goldstone, S. E. Bryan, A. Paton, and E. Putievsky, “Infraspecific taxonomy and essential oil chemotypes in sweet basil, Ocimum basilicum, ” Phytochemistry, vol. 43, pp.1033- 1039, 1996. [19] E. Klimánková, K. Holadova, J. Hajslova, T. Cajka, J. Poustka, and M. Koudela, “Aroma profiles of five basil (Ocimum basilicum L.) cultivars grown under conventional and organic conditions,” Food Chem, vol. 107, pp. 464-472, 2008. [20] S. Amrani, H. Harnafi, D. Gadi, H. Mekhfi, A. Legssyer, M. Aziz, et al, “Vasorelaxant and anti-platelet aggregation effects of aqueous Ocimum basilicum extract, ” J Ethnopharmacol, vol. 125, pp. 157-162, 2009. [21] H. Harnafi, M. Aziz, and S. Amrani, “Sweet basil (Ocimum basilicum L.) improves lipid metabolism in hypercholesterolemic rats, ” E Spen M.E. Jarvik, and R. Kopp, “An improved one-trial learning situation in mice,” Psychol. Rep, vol. 21, pp. 221–224, 1967. [22] D.K. Rush, “Scopolamine amnesia of passive avoidance: a deficit of information acquisition,” Behav. Neural Biol, vol. 50, pp. 255–274, 1988. [23] G. L. Ellman, K. D. Courtney, V. Andres, and R. M. Featherstone, “A new and rapid colorimetric determination of actetylcholinesterase activity”, Biochem. Pharmacol, vol. 7, pp. 88-95, 1961. [24] M.E. Jarvik, and R. Kopp, “An improved one-trial learning situation in mice,” Psychol. Rep, vol. 21, pp. 221–224, 1967. [25] D. Dhingra, M. Parle, and S.K. Kulkarni, “Memory enhancing activity of Glycyrrhiza glabra in mice,” J. Ethnopharmacol, vol. 91, pp. 361– 365, 2004. [26] M. Dokania, K. Kishore, and P. Sharma, “Effect of Ocimum sanctum extract on sodium nitrite-induced experimental amnesia in mice,” Thai J Pharm Sci, vol. 35, pp. 123-130, 2011. [27] S. Kumar, S. Rao, S. Nayak, and N. Sareesh, “Effect of Ocimum sanctum (Linn) extract on restraint stress induced behavioral deficits in male wistar rats, ” Pharmacol Online, vol. 3, pp. 394-404, 2007. [28] H. Joshi and M. Parle, “Cholinergic basis of memory improving effect of Ocimum tenuiflorum linn”, Indian J Pharm Sci, vol. 68, pp. 364, 2006. [29] K. S. Bora, S. Arora, and R. Shri, “Role of Ocimum basilicum L. in prevention of ischemia and reperfusion-induced cerebral damage, and motor dysfunctions in mice brain”, J Ethnopharmacol, vol. 137, pp. 1360-1365, 2011. [30] I. Gülçin, M. Elmasta, and H. Y. Aboul-Enein, “Determination of antioxidant and radical scavenging activity of Basil (Ocimum basilicum L. Family Lamiaceae) assayed by different methodologies,” Phytother Res, vol. 21, pp. 354-361, 2007. [31] H. J. Chang, H. J. Kim, and H. S. Chun, “Quantitative structure-activity relationship (QSAR) for neuroprotective activity of terpenoids,” Life Sciences, vol. 80, no. 9, pp. 835–841, 2007. [32] L. Mu, J. Kou, D. Zhu, and B. Yu, “Comparison of neuroprotective effects of flavonoids, terpenoids, and their combinations from Ginkgo biloba on ischemia-reperfusion—injured mice”, Pharmaceutical Biology, vol. 45, no. 9, pp. 728–733, 2007. [33] I. Kivrak, M. E. Duru, M. Ozturk, N. Mercan, M. Harmandar, and G. Topcu, “Antioxidant, anticholinesterase and antimicrobial constituents from the essential oil and ethanol extract of Salvia potentillifolia”, Food Chemistry, vol. 116, no. 2, pp. 470- 479, 2009. [34] K. Shiomi, “Meroterpenoids with various biological activities produced by fungi,” Pure and Applied Chemistry, vol. 71, no. 6, pp. 1059–1064, 1999. [35] S. U. Savelev, E. J. Okello, and E. K. Perry, “Butyryl- and acetylcholinesterase inhibitory activities in essential oils of Salvia species and their constituents”, Phytotherapy Research, vol. 18, no. 4, pp. 315–324, 2004. |
en_US |